The effects of guarana (Paullinia cupana) supplementation in capsules, for 30 days, were evaluated for the following dosages: placebo, 200 mg/day, and 400 mg/day. Clinical symptomatology, hematological, biochemical, and renal function parameters were evaluated in chronic kidney disease patients undergoing hemodialytic treatment. Most patients in the groups of 200 mg/day and 400 mg/day of guarana reported increased mood/energy, decreased fatigue, and increased appetite. The rate of patients reporting increased headache, insomnia, gastric discomfort, and nausea/vomiting was higher in the 400 mg/day group, while most patients in the placebo group and 200 mg/day of guarana group did not report any changes. The 200 mg/day and 400 mg/day groups had higher hemoglobin and hematocrit values after 30 days of supplementation when compared to the placebo group. Additionally, a reduction in hematological parameters and increase in glucose were seen in the placebo group. Guarana, especially at a dosage of 200 mg/day, is safe and effective in improving clinical symptoms and maintaining hemoglobin and hematocrit values.

瓜拉那（Paullinia cupana的影响评估在胶囊中补充30天的以下剂量：安慰剂，200 mg /天和400 mg /天。在接受血液透析治疗的慢性肾脏疾病患者中评估了临床症状，血液学，生化和肾功能参数。瓜拉那200 mg /天和400 mg /天的组中的大多数患者报告说情绪/精力增加，疲劳减轻和食欲增加。在400毫克/天的组中，报告头痛，失眠，胃部不适和恶心/呕吐的患者的发生率更高，而安慰剂组和瓜拉那组的200 mg /天的大多数患者均未报告任何变化。与安慰剂组相比，补充30天后200 mg / day和400 mg / day组的血红蛋白和血细胞比容值较高。此外，安慰剂组的血液学参数降低，血糖升高。瓜拉纳，尤其是200毫克/天的剂量，在改善临床症状以及维持血红蛋白和血细胞比容值方面是安全有效的。